ESR1 and cancer: These cancers are often treated with ERα targeted therapies, such as receptor antagonists (antiestrogens) including tamoxifen (TAM) or fulvestrant (ICI), or aromatase inhibitors like anastrozole or letrozole that inhibit ligand (17β-estradiol) production.